Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 2/20 | 0.36 |
| ▸ | TLR1 | Q15399 | 2/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5182464 | 0.90 | PTGS2 (0.38) | TLR2TLR1 | |
| SCHEMBL5166433 | 0.85 | CA12 (0.42) | TLR2TLR1ADORA3MAPTMEN1 | |
| SCHEMBL5169223 | 0.84 | GRIA1 (0.38) | — | |
| SCHEMBL5168903 | 0.83 | GRIK1 (0.35) | — | |
| SCHEMBL5190085 | 0.82 | GRIA1 (0.39) | — | |
| SCHEMBL5166749 | 0.80 | GRIA1 (0.37) | — | |
| SCHEMBL5165979 | 0.78 | GRIA1 (0.34) | — | |
| SCHEMBL5168348 | 0.77 | CA12 (0.31) | — | |
| SCHEMBL5168343 | 0.77 | GRIA1 (0.37) | — | |
| SCHEMBL5455598 | 0.77 | GRIK1 (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773788-B1 | Quinazoline derivatives | NOVARTIS AG (CH) | 2012-11-14 | — | — | EP | claimed |
| US-8299085-B2 | Quinazoline derivatives | NOVARTIS AG (CH) | 2012-10-30 | — | — | US | claimed |
| EP-1773788-B1 | Quinazoline derivatives | NOVARTIS AG (CH) | 2012-11-14 | — | — | EP | disclosed |
| US-8299085-B2 | Quinazoline derivatives | NOVARTIS AG (CH) | 2012-10-30 | — | — | US | disclosed |
| US-8299085-B2 | Quinazoline derivatives | NOVARTIS AG (CH) | 2012-10-30 | — | — | US | disclosed |
| US-8299085-B2 | Quinazoline derivatives | NOVARTIS AG (CH) | 2012-10-30 | — | — | US | disclosed |
| US-20070208018-A1 | Quinazoline Derivatives | NOVARTIS AG (CH) | 2007-09-06 | — | — | US | disclosed |
| US-20070208018-A1 | Quinazoline Derivatives | NOVARTIS AG (CH) | 2007-09-06 | — | — | US | disclosed |
| US-20070208018-A1 | Quinazoline Derivatives | NOVARTIS AG (CH) | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208018-A1 | Quinazoline Derivatives | CYP3A5, CYP3A7, CYP3A4 | TLR2 3794/4885TLR1 3599/4885ADORA3 469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.